Optimizing mRNA Formulations In A Bottlenecked & Bifurcated Supply Chain
Source: Precision NanoSystems
During our Bioprocess Online Live event, mRNA Update: Beyond Prophylactic Vaccines, we asked an audience of several hundred biopharma professionals what they found most challenging about mRNA therapeutic development. The runaway leading response was screening, developing, and optimizing formulations during preclinical development. Here, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. address overcoming that challenge in the context of a fragmented supply chain and outsourced environment.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
Precision NanoSystems
This website uses cookies to ensure you get the best experience on our website. Learn more